At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ATNF 180 Life Sciences Corp
Pre-Mkt 04-24 08:30:48 EDT
0.8610
-0.0190
-2.16%
盘前0.8797
+0.0196+2.28%
08:27 EDT
High0.9000
Low0.8400
Vol24.25K
Open0.8800
D1 Closing0.8800
Amplitude6.82%
Mkt Cap4.46M
Tradable Cap2.69M
Total Shares5.19M
T/O21.31K
T/O Rate0.77%
Tradable Shares3.13M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Blair Jordan Reports 10.5% Stake in 180 Life Sciences Corp as of Feb 20 - SEC Filing
180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.